NCT06136390View on ClinicalTrials.gov

OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

July 30, 2024

Study Completion Date

December 30, 2024

Conditions
Schizophrenia Spectrum Disorders
Interventions
OTHER

Oxytocin

Oxytocin nasal spray in combination with mindfulness based group therapy (MBGT).

OTHER

Placebo

Placebo nasal spray in combination with mindfulness based group therapy (MBGT).

Trial Locations (1)

12203

RECRUITING

Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER